Comprehensive Parkinson's Disease CRO Solutions for Drug Discovery
Overcome the challenges of Parkinson's drug discovery with Cyagen. Our integrated platform offers validated animal models and expert CRO services, providing reliable and efficient research support to scientists developing novel PD therapeutics.
An Integrated Approach to PD Research & Its Challenges
As the second most common neurodegenerative disorder, Parkinson's Disease has a significant global impact with substantial unmet medical needs. Key research bottlenecks include the need for models that accurately recapitulate the key features of synucleinopathy and the complexity of evaluating motor and non-motor symptoms.
To address these challenges, Cyagen provides a fully integrated workflow, from experimental design to
final report delivery, ensuring your PD research project is efficient and seamlessly executed.
We have built a powerful, integrated research platform for Parkinson's Disease by
combining advanced animal models, in vivo pharmacology, and in vitro analytical techniques to meet your
diverse R&D needs.
{{ item.title }}
{{static_tabs[0].title}}
Our comprehensive portfolio of Parkinson's Disease (PD) models is centered on synucleinopathy,
the key pathological hallmark of the disease. The table below includes both our validated,
ready-to-use models for immediate deployment, and our advanced R&D platform for key pathogenic
mutations, available for custom projects and collaborative research.
| Target Class | Model Name | Key Features | Status | Details |
|---|---|---|---|---|
| Synucleinopathy | B6-hSNCA | Humanized SNCA (Wild-Type) | Ready-to-Use | View |
| B6-hSNCA (3'UTR) | Humanized SNCA (with 3'UTR) | Ready-to-Use | View | |
| hSNCA (A53T) | Humanized SNCA (A53T Mutation) | R&D | - |
Can't find the model you need?
Explore hundreds of additional off-the-shelf neuroscience models in our MouseAtlas database, or partner with
our scientific team to develop a custom-engineered model tailored to your exact research
specifications.
{{static_tabs[1].title}}
Precision Drug Administration
Our team is highly experienced in the precision dosing and administration
methods critical for PD research, including routes that target the central nervous system.
- Systemic Delivery: Intravenous (tail vein), Intraperitoneal, Subcutaneous, etc.
- CNS-Targeted Delivery: Stereotactic brain injection into key regions like the substantia nigra or striatum.
Neurobehavioral Assessment for PD
We provide a battery of behavioral paradigms essential for evaluating the core motor and
non-motor deficits associated with Parkinson's Disease.
| Behavioral Domain | Recommended Tests for PD Research | Function Tested |
|---|---|---|
| Motor Function & Coordination | Rotarod Test | Motor coordination, balance, ataxia |
| Pole Test | Bradykinesia, motor coordination | |
| Grip Strength | Muscle strength | |
| Gait Analysis | Fine motor coordination and balance | |
| Cognitive & Psychiatric | Open Field Test | Spontaneous locomotor activity-related behavior |
{{static_tabs[2].title}}
We offer a focused suite of analytical services to investigate the core
pathological and molecular features of Parkinson's Disease, and to evaluate the efficacy of
your therapeutic candidates.
| Analysis Category | Specific Services | Key Applications & Targets in PD Research |
|---|---|---|
| Pathology & Biomarker Analysis | Histology & IHC/IF | Visualize and quantify key pathological hallmarks, including α-synuclein aggregates (pS129, total) and assess dopaminergic neuron health and loss via Tyrosine Hydroxylase (TH) staining. |
| ELISA & Immunoassays | Accurately quantify levels of total and aggregated α-synuclein in brain tissue and other biological samples. | |
| Neurotransmitter Analysis (HPLC) | Measure the levels of dopamine and its key metabolites (DOPAC, HVA) in the striatum and other relevant brain regions to assess the integrity of the nigrostriatal pathway. | |
| Gene & Protein Expression | Western Blot | Assess changes in α-synuclein (SNCA) protein levels, post-translational modifications (e.g., phosphorylation), and aggregation status. |
| RT-PCR & qPCR | Analyze the expression of the SNCA gene and other relevant therapeutic or pathological target genes to understand mechanistic changes. |
Case Studies
Case Study 1: B6-hSNCA (3'UTR): Validating Human SNCA Expression
{{ item.label }}
{{v2.label}}
{{item.context}}
{{v2.context}}
{{item.title}}
{{ item.context }}
Case Study 2: B6-hSNCA: Confirming Orthologous Gene Replacement
{{ item.label }}
{{v2.label}}
{{item.context}}
{{v2.context}}
{{item.title}}
{{ item.context }}
Why Partner with Cyagen?
Comprehensive Model Solutions
Gain access to validated humanized SNCA models and leverage our expertise in developing custom models for other PD-related targets.
Integrated Efficacy Platform
Utilize our one-stop services—from motor function assessment to terminal neurochemical and pathological analysis.
Data-Driven Decision Support
Our stringent quality control and commitment to reproducibility deliver reliable data for your project decisions.
Expert-Led Study Design
Collaborate with our senior scientists for end-to-end support, from model selection to customized protocol design.
Request a Preclinical CRO Services Consultation
Partner with Cyagen to advance your preclinical studies. Share your project goals with us and receive customized support.
Cyagen values your privacy. We’d like to keep you informed about our latest offerings and insights. Your preferences:
You may unsubscribe from these communications at any time. See our Privacy Policy for details on opting out and data protection.
By clicking the button below, you consent to allow Cyagen to store and process the personal information submitted in this form to provide you the content requested.